Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is Kisspeptin-10? Benefits, Research & Safety
A decapeptide hormone critical for initiating puberty and regulating reproductive hormone release, with emerging research applications.
Also known as:
Metastin
KP-10
Kisspeptin 45-54
UK summary: Not a licensed UK medicine. Reproductive-endocrinology peptide investigated for hypothalamic amenorrhoea, IVF triggers, and diagnostic use. Genuine clinical-research interest with promising trial data; not a wellness product.
Quick Facts
Category
Hormonal & Endocrine
Half-Life
Short; approximately 27.6 minutes for kisspeptin-54, shorter for KP-10
UK Status
Not licensed. Research compound under clinical investigation.
EU Status
Not approved. Clinical trials ongoing at various centres.
Overview
Kisspeptin-10 (KP-10) is a 10-amino acid peptide derived from the larger kisspeptin-54 (formerly known as metastin), encoded by the KISS1 gene. Kisspeptins are now recognised as master regulators of the reproductive axis, playing a critical role in initiating puberty and maintaining normal reproductive function.
Kisspeptins act on the KISS1R receptor (formerly GPR54) located on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. Activation of this receptor stimulates GnRH release, which in turn triggers the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, ultimately affecting gonadal function.
Research into kisspeptin has provided fundamental insights into the regulation of puberty and fertility. Mutations in either KISS1 or KISS1R cause hypogonadotropic hypogonadism (failure to undergo puberty), demonstrating the system's essential role.
Kisspeptin-10 is being investigated for potential therapeutic applications in reproductive medicine, including treatment of hypothalamic amenorrhoea, support for IVF protocols, and diagnosis of reproductive disorders. Some clinical studies have been conducted, though no approved medications currently exist.
The peptide also has relevance to conditions such as polycystic ovary syndrome (PCOS) and the metabolic-reproductive interface, given kisspeptin's role as an integrator of energy status and reproduction.
Evidence standards summary
Kisspeptin-10 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
CLimited human evidenceOverall grade against our evidence grading methodology.
Not a licensed UK medicine. Reproductive-endocrinology peptide investigated for hypothalamic amenorrhoea, IVF triggers, and diagnostic use. Genuine clinical-research interest with promising trial data; not a wellness product.
02Human evidence grade
CLimited human evidenceStrength of evidence from published human trials.
03Preclinical evidence grade
AStrong human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not licensed. Research compound under clinical investigation.
- EU: Not approved. Clinical trials ongoing at various centres.
- Notes: Kisspeptin is actively being researched for therapeutic applications in reproductive medicine. No approved products exist yet. Research is particularly active at Imperial College London and other major centres.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Restores ovulation in any cause of female sub-fertility.
- Boosts testosterone in healthy men.
- Treats hypoactive sexual desire disorder.
- Safe to self-administer at home.
07Common internet claims
- Marketed by some private fertility clinics off-label.
- Sold by online retailers as a research-only injection.
- Promoted in 'hormonal optimisation' stacks alongside testosterone.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Triggers natural ovulation for IVF” | B | Yes | Moderate | Kisspeptin has been studied as an IVF trigger with promising results; it is not a licensed UK fertility medicine and is used in research settings only. |
| “Restores periods in functional hypothalamic amenorrhoea” | C | Limited | Moderate | Trial data are encouraging for hypothalamic amenorrhoea; not yet a licensed treatment. |
| “Sexual-arousal enhancer” | D | Limited | High | Some research suggests effects on sexual arousal pathways; this is not a licensed indication and trial data is preliminary. |
| “Available from research peptide suppliers — safe to self-administer” | E | No | High | Reproductive hormones should be assessed and managed by specialists; self-administration carries serious risk. |
09Safety uncertainty score
Moderate
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Specialist-supervised use in IVF trials shows good short-term tolerability.
- Unsupervised use risks disrupting HPG axis in unpredictable ways.
- Injection-site reactions.
- Theoretical risk of triggering ovarian hyperstimulation if used outside trial protocols.
11Drug-interaction uncertainty
Moderate
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
WADA: Sport status unclearWADA strict-liability framing applies.
13UK legal position
UK: Unlicensed (UK)
Not licensed. Research compound under clinical investigation.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Not approved. Clinical trials ongoing at various centres.
15What this page cannot tell you
- Whether a UK-purchased vial contains kisspeptin-10 at the labelled concentration.
- What dose and timing produce safe ovulation triggering outside an IVF setting.
- How chronic use would affect endogenous HPG-axis function.
- Whether off-label male / HSDD use carries the same safety profile as the research IVF use.
16Last reviewed
17Citation quality score
BModerate human evidenceQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- Imperial College London research is strong but kisspeptin-as-IVF-trigger is not yet in routine NHS practice.
- Male and HSDD outcome trials are limited.
- Long-term safety beyond a single trigger event is unstudied.
- Optimal dose / timing remains research-stage.
19Safer alternatives / established care pathways
- Specialist reproductive-medicine referral via NHS or HFEA-licensed private clinic for fertility concerns.
- Licensed gonadotrophins and IVF triggers (hCG, GnRH agonist) under specialist supervision.
- Endocrinology referral for HPG-axis investigation in suspected hypogonadism.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Kisspeptin-10 a licensed UK fertility medicine?
- Are there UK clinical trials I might be eligible for?
- What licensed treatments exist for my fertility / endocrine concern?
- If a clinic is offering kisspeptin outside a trial, what's the regulatory framing?
Discovery & History
The kisspeptin story began in 1996 when the KISS1 gene was identified as a metastasis suppressor gene in melanoma cells—hence the original name "metastin." The gene was found at the Hershey Medical Center in Pennsylvania, leading to the playful name "KISS1" (a reference to Hershey's Kisses chocolates).
For several years, KISS1/metastin was studied primarily in cancer research. The discovery of its critical role in reproduction came in 2003 when two independent groups discovered that mutations in the KISS1 receptor (GPR54) caused hypogonadotropic hypogonadism—failure to undergo puberty.
This discovery fundamentally changed understanding of reproductive neuroendocrinology. Kisspeptin was rapidly established as the key upstream regulator of GnRH release, effectively serving as the "on switch" for puberty and the gatekeeper of reproductive function.
Subsequent research revealed that kisspeptin neurons integrate multiple signals—including metabolic status, stress, and day length—to appropriately regulate reproduction. This helps explain why conditions like anorexia nervosa or extreme exercise suppress menstruation.
Active clinical research is ongoing into kisspeptin's therapeutic potential, with studies investigating its use in IVF, hypothalamic amenorrhoea, and as a diagnostic tool for reproductive disorders.
Mechanism of Action
Kisspeptin-10 works through a specific receptor to control the reproductive hormone axis:
**KISS1R (GPR54) Activation**
Kisspeptin-10 binds to and activates KISS1R on hypothalamic GnRH neurons:
- Triggers immediate GnRH release
- All isoforms of kisspeptin (KP-10, KP-13, KP-14, KP-54) activate the same receptor
- KP-10 contains the minimal sequence needed for full receptor activation
**GnRH-Gonadotropin Cascade**
Activation of GnRH neurons initiates the reproductive cascade:
- GnRH release from hypothalamus
- Stimulation of LH and FSH release from pituitary
- Effects on gonads (testosterone/oestrogen production, gametogenesis)
**Pulsatility and Desensitisation**
The mode of kisspeptin administration affects responses:
- Pulsatile kisspeptin maintains GnRH pulsatility
- Continuous kisspeptin administration can cause desensitisation
- This has implications for therapeutic applications
**Integration of Metabolic Signals**
Kisspeptin neurons receive and integrate multiple inputs:
- Leptin (energy status)
- Stress hormones
- Sex steroids (feedback)
- Circadian signals
- This explains the link between energy status and fertility
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent stimulation of LH and FSH release
- 2Potential treatment for hypothalamic amenorrhoea
- 3Possible IVF trigger alternative to hCG
- 4Diagnostic applications for reproductive disorders
- 5Research tool for studying reproductive physiology
- 6May offer advantages over GnRH analogues in certain contexts
Claim vs Evidence
How popular claims about Kisspeptin-10 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Triggers natural ovulation for IVF” | B | Yes | Moderate | Kisspeptin has been studied as an IVF trigger with promising results; it is not a licensed UK fertility medicine and is used in research settings only. |
| “Restores periods in functional hypothalamic amenorrhoea” | C | Limited | Moderate | Trial data are encouraging for hypothalamic amenorrhoea; not yet a licensed treatment. |
| “Sexual-arousal enhancer” | D | Limited | High | Some research suggests effects on sexual arousal pathways; this is not a licensed indication and trial data is preliminary. |
| “Available from research peptide suppliers — safe to self-administer” | E | No | High | Reproductive hormones should be assessed and managed by specialists; self-administration carries serious risk. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Variable depending on research application; 0.3-13 nmol/kg in clinical studies |
| Frequency | Single dose, pulsatile, or continuous depending on study design |
| Duration | Variable; acute studies to multi-week protocols |
| Notes | Kisspeptin-10 is not approved for therapeutic use. Clinical research is ongoing. The mode of administration (pulsatile vs continuous) significantly affects outcomes. All use should be in research settings under appropriate supervision. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous infusion (most clinical research)
- Subcutaneous injection (some protocols)
| Half-Life | Stability |
|---|---|
| Short; approximately 27.6 minutes for kisspeptin-54, shorter for KP-10 | Requires careful handling; lyophilised form for storage |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Transient hot flushes
- Injection site reactions
- Headache
- Generally well-tolerated in clinical studies
Rare Risks & Concerns
- Limited long-term data in humans
- Potential for desensitisation with continuous use
- Unknown effects of chronic administration
Contraindications
- Hormone-sensitive cancers (stimulates sex hormones)
- Pregnancy (effects unknown)
- Conditions where hormonal stimulation is contraindicated
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed. Research compound under clinical investigation.
🇪🇺 European Union
Not approved. Clinical trials ongoing at various centres.
Kisspeptin is actively being researched for therapeutic applications in reproductive medicine. No approved products exist yet. Research is particularly active at Imperial College London and other major centres.
Clinical Studies Summary
Kisspeptin in Women with Hypothalamic Amenorrhoea
Clinical studies demonstrating that kisspeptin can restore LH pulsatility in women with hypothalamic amenorrhoea.
J Clin Invest and related journalsView on PubMed
Kisspeptin as IVF Trigger
Research investigating kisspeptin as an alternative to hCG for oocyte maturation in IVF, potentially reducing OHSS risk.
Fertility and reproductive medicine journalsView on PubMed
Looking for Kisspeptin-10?
Source research-grade Kisspeptin-10 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Kisspeptin-10
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Kisspeptin-10 a licensed UK fertility medicine?
- Are there UK clinical trials I might be eligible for?
- What licensed treatments exist for my fertility / endocrine concern?
- If a clinic is offering kisspeptin outside a trial, what's the regulatory framing?
UK regulatory & safety context
Related Research Guides
Related Peptides
GHRP-2
A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.
Learn moreOxytocin
A natural hormone and neurotransmitter involved in social bonding, childbirth, lactation, and emotional regulation with therapeutic applications.
Learn moreGnRH
The master hypothalamic hormone controlling reproductive function, with both agonist and antagonist analogues used therapeutically.
Learn more